3002.13.00.10/Denosumab Monoclonal Antibody/Canada

Denosumab Monoclonal Antibody from Canada

Denosumab (Prolia) fully human monoclonal antibody inhibiting RANKL for osteoporosis. Classifies unmixed under HTS 3002.13.0010 per chapter immunological definitions. Bulk for formulation.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Include RANKL inhibition data

• FDA prior notice via PNSI system mandatory

• Document non-osteo appliance use